美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Veraxa Biotech Holding AG

1.52

-0.1100-6.75%

盤前：1.600.0800+5.26%05:19 EDT

成交量：5.23萬

成交額：8.10萬

市值：2.15億

市盈率：7.10

高：1.70

開：1.61

低：1.50

收：1.63

52周最高：27.36

52周最低：1.27

股本：1.41億

流通股本：4,095.75萬

量比：0.22

換手率：0.13%

股息：- -

股息率：- -

每股收益(TTM):0.2142

每股收益(LYR):-5.8037

淨資產收益率：-871.42%

總資產收益率：-49.99%

市淨率：-11.16

市盈率(LYR):-0.26

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Veraxa Biotech AG：體外概念驗證研究取得積極成果，有望融合雙方技術與專長開創全新AOC療法

Veraxa Biotech與Secarna Pharmaceuticals達成抗體寡核苷酸偶聯聯盟研究里程碑

Veraxa Biotech Holding AG強化專利佈局，築牢核心技術平台與產品管線護城河

Veraxa Biotech攜手OmniAb，推進創新雙特異性抗體偶聯藥物Vxa-222項目取得新進展

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/VRXA"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.52,"timestamp":1789502400000,"preClose":1.63,"halted":0,"volume":52303,"hourTrading":{"tag":"盘前","latestPrice":1.6,"preClose":1.52,"latestTime":"05:19 EDT","volume":3553,"amount":5921.7833235,"timestamp":1789550354467,"change":0.08,"changeRate":0.052632,"amplitude":0.105263},"delay":0,"changeRate":-0.06748466257668705,"floatShares":40957496,"shares":141407813,"eps":0.2142,"marketStatus":"盤前交易","change":-0.11,"latestTime":"09-16 05:27:54 EDT","open":1.61,"high":1.6993,"low":1.5,"amount":81002.6132449,"amplitude":0.12227,"askPrice":1.85,"askSize":100,"bidPrice":1.4,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.6,"preClose":1.52,"latestTime":"05:19 EDT","volume":3553,"amount":5921.7833235,"timestamp":1789550354467,"change":0.08,"changeRate":0.052632,"amplitude":0.105263},"postHourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.52,"latestTime":"19:30 EDT","volume":114,"amount":174.5,"timestamp":1789515005036,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.21584144036174788},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":40957496,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":0.21584144036174788,"shares":141407813,"dividePrice":0,"high":1.6993,"amplitude":0.12227,"preClose":1.63,"low":1.5,"week52Low":1.27,"pbRate":"-11.16","psRate":"7514.10","week52High":27.36,"institutionHeld":0,"latestPrice":1.52,"committee":0.333333,"eps":0.2142,"divideRate":0,"volume":52303,"delay":0,"ttmEps":0.2142,"open":1.61,"prevYearClose":18.65,"prevWeekClose":1.65,"prevMonthClose":1.35,"prevQuarterClose":1.88,"fiveDayClose":1.6,"twentyDayClose":1.86,"sixtyDayClose":4.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-09-15","current":7.096172,"percent":0.176471,"low":-3.022108,"twenty":-2.801269,"median":-1.377349,"eighty":-1.094949,"high":-0.413162,"avg":-1.785283,"sd":0.924748,"marketCap":230494735},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-04","current":-2.622384,"twenty":-1.391748,"median":-1.265172,"eighty":-0.552029,"marketCap":216353953},{"date":"2026-09-11","current":-2.842124,"twenty":-2.738773,"median":-1.34261,"eighty":-1.03732,"marketCap":233322891},{"date":"2026-09-15","current":-2.834144,"twenty":-2.801269,"median":-1.377349,"eighty":-1.094949,"marketCap":230494735}],"updateTime":1789550874139},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1172247840","title":"Veraxa Biotech AG：體外概念驗證研究取得積極成果，有望融合雙方技術與專長開創全新AOC療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1172247840","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172247840?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:44","pubTimestamp":1787571855,"startTime":"0","endTime":"0","summary":"Veraxa Biotech AG近日宣布，一项成功的体外概念验证研究初步显示出令人振奋的潜力——通过整合双方的尖端技术与深厚专业知识，有望催生新一代抗体偶联物的诞生。由此产生的协同效应，或许正是解锁AOC药物更广阔应用空间的关键钥匙。Veraxa Biotech AG方面对此成果表示高度认可，并认为这是公司发展战略中的一个重要里程碑。借助此次合作所积累的经验和数据，后续的研发管线有望得到显著充实和加速。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156560832","title":"Veraxa Biotech與Secarna Pharmaceuticals達成抗體寡核苷酸偶聯聯盟研究里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1156560832","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156560832?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:42","pubTimestamp":1787571733,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG及其合作伙伴Secarna Pharmaceuticals，在抗体寡核苷酸偶联物联盟框架下，成功跨越了一项关键研究里程碑。通过将抗体的靶向特异性与寡核苷酸的治疗潜力相结合，该联盟正致力于开发新一代精准医疗方案。双方团队对此次合作成果表示高度认可，并强调这一里程碑的达成，凝聚了跨学科研究的智慧与不懈努力。展望未来，Veraxa与Secarna将继续深化协作，加速推进项目向临床前及临床阶段转化，以期为患者带来更具变革性的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178040350","title":"Veraxa Biotech Holding AG強化專利佈局，築牢核心技術平台與產品管線護城河","url":"https://stock-news.laohu8.com/highlight/detail?id=1178040350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178040350?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 19:01","pubTimestamp":1785322874,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正全力扩充其专利组合，旨在为公司的核心技术平台与候选产品构建起坚实的知识产权堡垒。这一举措，不仅彰显了企业对创新成果的深度保护，更预示着其在生物科技领域长期战略布局的进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183111407","title":"Veraxa Biotech攜手OmniAb，推進創新雙特異性抗體偶聯藥物Vxa-222項目取得新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1183111407","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183111407?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:01","pubTimestamp":1785150073,"startTime":"0","endTime":"0","summary":"Veraxa Biotech Holding AG正积极推进其新型双特异性抗体药物偶联物（ADC）项目Vxa-222。这一里程碑式的进展，源自其与OmniAb共同开展的发现合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VRXA\",params:#limit:6,delay:false,,,undefined,":[]}}